NewAmsterdam Pharma (NAMS) Net Cash Flow (2023 - 2026)

NewAmsterdam Pharma has reported Net Cash Flow for 4 years, with the latest figure at -$31.0 million in Q1 2026.

• Quarterly Net Cash Flow fell 14.59% year-over-year to -$31.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$297.1 million (down 210.95% YoY) and the FY2025 annual result came in at -$293.2 million, down 166.92% from the prior year.
• Net Cash Flow climbed to -$31.0 million in Q1 2026 per NAMS's latest filing, from -$48.3 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $357.0 million in Q4 2024 and troughed at -$193.4 million in Q2 2025.
• A 4-year average of $376166.7 and a median of -$30.3 million in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow soared 1179.15% in 2024, then plunged 290.43% in 2025.
• Over 4 years, Net Cash Flow stood at -$33.1 million in 2023, then jumped by 1179.15% to $357.0 million in 2024, then slumped by 113.54% to -$48.3 million in 2025, then soared by 35.76% to -$31.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$31.0 million, -$48.3 million, and -$24.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.